Otonomy Announces Top-Line Results for the Phase 3 Clinical Trial of OTIVIDEX® in Patients with Ménière’s Disease
Implant may improve lives of those with serious balance disorder
Otonomy Completes Patient Enrollment for Phase 3 Trial of OTIVIDEX® in Ménière’s Disease
Auris Medical Announces Positive Interim Data from TRAVERS Phase 2 Study with AM-125 in Vertigo
September 03, 2020 08:30 ET | Source: Auris Medical AG
Dose dependent improvement in balance tests over placebo in Part A of TRAVERS trial
Improvement 1.9 to 2.4 times greater with highest dose than with placebo
Trial to proceed with Part B to test AM-125 10 and 20 mg vs. placebo
Hamilton, Bermuda, September 3, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced positive top-line data from the interim analysis of its Phase 2 “TRAVERS” trial with intranasal betahistine in vertigo (AM-125).
New AI model reads MRI image of inner ear disorder
By Shim Hyun-taiPublished 2020.06.15 17:40Updated 2020.06.15 17:40
A research team of Samsung Medical Center has developed an artificial intelligence model for diagnosing Meniere’s disease by analyzing images obtained by magnetic resonance imaging (MRI).
“[…] newly developed technology is the first deep learning-based AI model to diagnose Meniere’s disease”
Otonomy Provides Update on Clinical Trials and Development Programs
June 15, 2020 16:05 ET | Source: Otonomy, Inc.
- Results from Phase 3 trial of OTIVIDEX® in Ménière’s disease expected in first quarter of 2021
- Results from Phase 1/2 trial of OTO-313 in tinnitus expected in July 2020
- Results from Phase 1/2 trial of OTO-413 in hearing loss expected in fourth quarter of 2020
SAN DIEGO, June 15, 2020 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided an update on its product pipeline and the timeline to results for the company’s three ongoing clinical trials, including the Phase 3 trial of OTIVIDEX in Ménière’s disease. The company will host a conference call and webcast today at 4:30 p.m. ET to review these updates.
Sound Pharma advances pivotal Phase 3 clinical trials in Meniere’s Disease
Published: Jun 08, 2020
SEATTLE, June 8, 2020 /PRNewswire/ — Sound Pharmaceuticals is pleased to announce that the FDA has allowed its pivotal Phase 3 clinical protocol for SPI-1005 in the Treatment of Patients with Meniere’s Disease (STOPMD-3).
NEWS RELEASE 8-APR-2020
Ménière’s disease: New clinical practice guideline
To enhance diagnostic accuracy and treatment
AMERICAN ACADEMY OF OTOLARYNGOLOGY – HEAD AND NECK SURGERY
Auris Medical Provides Update on Intranasal Betahistine Development Program
Auris Medical Provides Update on Ongoing Clinical Trials with Intranasal Betahistine
Singer opens up about suicidal thoughts after his Ménière’s disease diagnosis – what is the disorder?
Successful project to help dizziness sufferers expands to Europe
FDA grants Fast Track Designation for SPI-1005 in the Treatment of Meniere’s Disease
Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere’s Disease
Auris Medical Announces Randomization of First Patient in AM-125 Phase 2 Trial in Acute Vertigo
Sound Pharmaceuticals Completes Phase 2 Study of SPI-1005 for the Treatment of Patients with Meniere’s Disease